ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Of Perugia
• Treatments: Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• Consecutive patients who had

• planned laparoscopic surgery for

• colorectal cancer will be included in the study provided no exclusion criteria will be found

Exclusion Criteria:

• age < 18 years

• surgery for non-cancer disease

• duration of surgery < 45 min

• other indication for anticoagulant therapy

• known cerebral metastases

• kidney or liver failure

• known hemorrhagic diathesis or high risk for bleeding

• history of intracerebral bleeding or neurosurgery within 6 months, history of heparin induced thrombocytopenia

• pregnancy or lactation

• refusal of informed consent.